2
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Prostatic Neoplasms
29
Breast Neoplasms
28
Brain Neoplasms
21
Neoplasms
16
Glioma
10
Pancreatic Neoplasms
9
Head and Neck Neoplasms
8
Lymphoma
7
Uterine Cervical Neoplasms
6
Urinary Bladder Neoplasms
6
Rectal Neoplasms
6
Glioblastoma
6
Colonic Neoplasms
6
Carcinoma, Hepatocellular
6
Lymphoma, Non-Hodgkin
5
Lung Neoplasms
5
Astrocytoma
5
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Liver Neoplasms
4
Disease
4
Central Nervous System Neoplasms
4
Stomach Neoplasms
3
Spinal Cord Neoplasms
3
Sarcoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Esophageal Neoplasms
3
Carcinoma in Situ
3
Retinoblastoma
2
Pathologic Complete Response
2
Interventions
Ibandronic Acid
8
Gemcitabine
8
Doxorubicin
6
Cyclophosphamide
6
Zoledronic Acid
5
Radiation
4
Nivolumab
4
Irinotecan
4
pembrolizumab
3
Vincristine
3
Temozolomide
3
Magnetic Resonance Spectroscopy
3
Ipilimumab
3
Docetaxel
3
Denosumab
3
Cisplatin
3
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
3
regorafenib
2
pegfilgrastim
2
Tranexamic Acid
2
Trabectedin
2
Surveys and Questionnaires
2
Sunitinib
2
Standard of Care
2
Radiotherapy, Intensity-Modulated
2
Radiotherapy
2
Radiosurgery
2
Quality of Life
2
Proton Therapy
2
Observation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Bone Neoplasms
×
Magnetic Resonance Imaging
×
Clear all
NCT04394052
2020-07-21
TUMOSTEO II
Central Hospital, Nancy, France
Recruiting
740 enrolled